Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP1002 in Refractory/Relapsed AML
NCT05190471Phase 1Recruiting
- Sponsor
- Bio-Path Holdings, Inc.
- Start
- Aug 2022
- Primary completion
- Mar 2027
- Modality
- Modified DNA Oligonucleotides, Targeted Liposomes, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of BP1002 in acute myeloid leukemia (AML) (2 arms), sponsored by Bio-Path Holdings, Inc. Primary endpoints: Dose Limiting Toxicity at 30 days, Treatment-Emergent Adverse Events at 30 days and 9 more. Started Aug 2022; status: recruiting.
02
Drugs
BP1002
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05190471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05190471.